Exclusive Summary

• - Fully off-patent, globally mature molecule; US-registered 500mg/10ml injection enables fast reference-based registrations and tender access.
• - Addresses severe HSV/VZV cases (encephalitis, neonatal HSV, immunocompromised zoster), with large underlying infected populations and steady hospital stocking demand.
• - Listed on the WHO Model List and recommended as first-line IV therapy in major guidelines for severe herpesvirus infections, ensuring entrenched standard-of-care use.
• - Many global generics exist, but periodic shortages create openings; 500mg/10ml ready-to-dilute solution offers workflow advantages over 250mg lyophilized vials in some markets.
• - US registration and cGMP compliance provide quality credibility, while generic pricing (typically >80–90% lower than originator) supports cost containment and reliable supply.